The Food and Drug Administration on Friday gave tentative approval to Indian drugmaker Aurobinda Pharma to make a generic version of the brand-name anti-HIV medication Sustiva. The drug will be immediately available for purchase and distribution in developing countries through the five-year, $15 billion President's Emergency Plan for AIDS Relief. The generic drug will not be sold in the United States or other Western nations because of patent protections on Sustiva. "By making these safe and effective treatments available through the PEPFAR program as quickly as possible, we are helping to combat" the global AIDS pandemic, said Health and Human Services secretary Mike Leavitt in a press release.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














